Showing results (261-270 of 329) with videos related to
Sort By:
Pageof 33
Circulation|June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.Journal of the American Heart Association|September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF TrialAnthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.Journal of the American Heart Association|March 26, 2013
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trialDaniel E Singer, Anne S Hellkamp, Jonathan P Piccini, et al.Circulation|October 31, 2013
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trialLars Wallentin, Daniel Lindholm, Agneta Siegbahn, et al.Thrombosis Research|April 24, 2017
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trialYihong Sun, Dayi Hu, Susanna Stevens, et al.Hypertension (Dallas, Tex. : 1979)|May 10, 2021
Pediatric and Adult Ambulatory Blood Pressure Thresholds and Blood Pressure Load as Predictors of Left Ventricular Hypertrophy in AdolescentsGilad Hamdani, Mark M Mitsnefes, Joseph T Flynn, et al.Cardiology and Therapy|August 4, 2019
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AFLeo Ungar, Fatima Rodriguez, Anne S Hellkamp, et al.Annals of Internal Medicine|June 20, 2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialKenneth W Mahaffey, Daniel Wojdyla, Graeme J Hankey, et al.Journal of the American Heart Association|March 5, 2015
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trialDaniel E Singer, Anne S Hellkamp, Zhong Yuan, et al.Circulation|July 28, 2010
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary interventionMauricio G Cohen, Drew A Purdy, Joseph S Rossi, et al.Pageof 33